The Algorithm in the Angio Suite: Heartflow's Surge Signals a New Era for Cardiac Care

SAN FRANCISCO, CA – November 12, 2026 – For decades, the standard response to suspected coronary artery disease has been a trip to the catheterization lab. It is a sterile, anxiety-inducing environment where a tube is threaded through a patient's blood vessels to the heart—an invasive, expensive, and sometimes entirely unnecessary procedure. Today, the gap between how cardiac diagnostics have historically worked and how they should work is rapidly closing, driven by an algorithmic revolution that is turning standard CT scans into hyper-accurate, 3D physiological models.

At the forefront of this shift is Heartflow, Inc., a medical technology company that has spent the last decade trying to convince the medical establishment that artificial intelligence can safely replace the scalpel for diagnostic triage. If the company's third-quarter 2026 financial results are any indication, the medical establishment is finally, overwhelmingly, convinced.

Heartflow reported total revenue of $72.9 million for the quarter ended September 30, representing a staggering 57% increase year-over-year. The surge was propelled by its U.S. operations, which generated $67.9 million—a 60% jump and the fastest domestic growth the company has seen in 11 quarters. In response to the robust adoption of its non-invasive diagnostic tools, the company raised its full-year 2026 revenue guidance for the second time this year, now projecting between $262 million and $264 million.

Closing the Profitability Gap

For a company that has long promised to revolutionize cardiovascular care, the financial reality has historically been one of heavy cash burn and steep operational losses. However, the third-quarter data paints a picture of a business that is rapidly scaling out of its startup phase and closing in on sustained profitability.

Gross margin expanded to an impressive 83.6% (83.8% on a non-GAAP basis), up from 76.5% in the same period last year. This is a margin profile more akin to an enterprise software behemoth than a traditional medical device manufacturer. The expansion is largely attributable to increased case volumes and the successful rollout of AI-driven production efficiencies that have dramatically reduced the cost of generating each patient's physiological model.

"Our third quarter was excellent, with revenue accelerating for the third consecutive quarter and U.S. revenue growing at its fastest pace in 11 quarters," said John Farquhar, President and CEO of Heartflow, in the company's earnings release. "Our core FFRCT business remains durable, our installed base continues to expand rapidly, and activations of Heartflow Plaque Analysis are ramping ahead of plan."

Crucially, the top-line growth is finally outpacing the company's operational spend. Heartflow's GAAP net operating loss narrowed to $13.8 million, while its non-GAAP net operating loss shrank to just $5.0 million, down from $11.1 million a year ago. The overall net loss dropped precipitously to $11.5 million ($0.13 per share), a vast improvement from the $50.9 million ($1.04 per share) hemorrhage in the third quarter of 2025—a period that was heavily weighed down by debt extinguishment and warrant remeasurement charges.

Yet, a closer look at the non-GAAP reconciliations reveals the ongoing complexities of scaling a digital health empire. The company excluded $1.3 million in "certain litigation expenses" for the quarter ($3.7 million year-to-date) and a previously recorded $7.5 million asset impairment charge. While management views these as non-recurring, they serve as a reminder of the friction inherent in navigating the highly regulated, hyper-competitive medtech landscape. Armed with $253 million in cash and investments, analysts tracking the sector suggest the firm is comfortably capitalized to reach its target of cash-flow profitability by mid-2028.

The Algorithm at the Bedside

The financial turnaround is intrinsically linked to a profound shift in clinical guidelines. For years, the adoption of Heartflow's Fractional Flow Reserve Computed Tomography (FFRCT) was a localized phenomenon, championed by early adopters but viewed with caution by the broader cardiology community.

That changed with the updated AHA/ACC Chest Pain Guidelines, which elevated Coronary Computed Tomography Angiography (CCTA) to a Class 1 recommendation for stable chest pain, and gave FFRCT a Class 2a recommendation. Suddenly, the algorithmic approach was not just an alternative; it was the recommended front-line standard of care.

Real-world clinical data has provided the necessary ammunition to change entrenched hospital protocols. At the European Society of Cardiology (ESC) 2026 congress, late-breaking data from the independent FUSION trial demonstrated that the Heartflow pathway safely reduced unnecessary invasive coronary angiographies by a remarkable 44%. For patients, this means avoiding the physical risks and psychological stress of an invasive procedure. For hospital administrators, it represents a massive reduction in systemic waste.

Furthermore, the company's newer Plaque Analysis tool is gaining aggressive traction. Data presented at the AHA 2026 scientific sessions from the DECIDE Registry showed that utilizing the plaque analysis was associated with 34% fewer major cardiovascular disease events and half the rate of heart attacks at one year. Payers are taking notice; reimbursement coverage for the Plaque Analysis tool has expanded to cover roughly 82% of covered lives in the United States, up from 78% just one quarter prior.

A Crowded Field of Virtual Cardiologists

Heartflow is not operating in a vacuum. The lucrative intersection of artificial intelligence and cardiology has attracted a swarm of well-funded competitors, setting the stage for a fierce battle over the future of cardiovascular imaging.

Startups like Cleerly have built formidable businesses by focusing intensely on characterizing and quantifying arterial plaque, challenging Heartflow's historical dominance in blood flow simulation. While Heartflow has aggressively expanded into plaque analysis to match this threat, the competition is pushing the boundaries of what AI can diagnose.

Similarly, Elucid recently secured FDA 510(k) clearance in September 2026 for its FFR-IQ software, which estimates fractional flow reserve from CCTA by incorporating both coronary anatomy and plaque composition. Notably, Elucid utilized Heartflow's technology as its predicate device for the clearance, a backhanded compliment that underscores Heartflow's status as the industry pioneer while simultaneously highlighting the creeping commoditization of the space.

Beyond nimble startups, legacy imaging titans like Siemens Healthineers, GE HealthCare, and Philips loom large. These conglomerates possess the capital and the hardware footprint to bundle AI software directly into their imaging machines, presenting a structural challenge to standalone software providers. However, industry observers note that Heartflow's deep moat—built on over 625 peer-reviewed publications and real-world validation in over 365,000 patients—provides a level of clinical trust that cannot be easily replicated by newer entrants or hardware-centric giants.

The True Cost of Precision

To maintain its leadership position, the company is spending aggressively. Research and development expenses surged 70% year-over-year to $29.5 million in the third quarter. This capital is fueling the development of next-generation tools, including the highly anticipated "Plaque Tracker" slated for launch in 2027, which aims to monitor disease progression over time.

The ultimate prize for Heartflow and its competitors lies beyond symptomatic patients. If clinical trials can prove the efficacy of using CCTA and AI analysis for screening asymptomatic, high-risk individuals, the total addressable market could double to an estimated $11 billion by the end of the decade.

As the company scales, the narrative is shifting from a story about technological novelty to one of systemic transformation. By turning the world's leading cause of death into a condition that can be mapped, measured, and managed without a single incision, the integration of AI into the cardiology suite is proving to be a rare instance where corporate growth aligns perfectly with the betterment of the human experience.